Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.61 |
| ▸ | HTR2C | P28335 | 2/20 | 0.45 |
| ▸ | DRD2 | P14416 | 2/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.45 |
| ▸ | DRD1 | P21728 | 2/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.40 |
| ▸ | HTR2B | P41595 | 1/20 | 0.40 |
| ▸ | DRD4 | P21917 | 1/20 | 0.39 |
| ▸ | DRD5 | P21918 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8816862 | 1.00 | HTR2A (0.61) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL30843843 | 0.97 | HTR2A (0.59) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL19565413 | 0.84 | KDM1A (0.47) | HTR2AMAOB | |
| SCHEMBL19059879 | 0.82 | MAPT (0.55) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL28950833 | 0.82 | HTR2A (0.59) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL19393871 | 0.81 | HTR2A (0.48) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL5740020 | 0.81 | HTR2A (0.48) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL13672458 | 0.80 | HTR2A (0.57) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL6361874 | 0.80 | HTR2A (0.47) | HTR2AHTR2CDRD2SLC6A2SLC6A4 | |
| SCHEMBL18942811 | 0.80 | CES1 (0.47) | HTR2AMAOAMAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117843460-A | Preparation method for producing 10, 10-dimethyl anthrone | 中国科学院大连化学物理研究所 | 2024-04-09 | — | — | CN | claimed |
| CN-117843460-B | Preparation method for producing 10, 10-dimethyl anthrone | 中国科学院大连化学物理研究所 | 2026-04-14 | — | — | CN | disclosed |
| US-20250362303-A1 | CIRCULARLY PERMUTATED HALOALKANE TRANSFERASE FUSION MOLECULES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2025-11-27 | — | — | US | disclosed |
| US-12371676-B2 | Circularly permutated haloalkane transferase fusion molecules | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. (DE) | 2025-07-29 | — | — | US | disclosed |
| CN-119841832-A | Compounds having SMARCA2 inhibitory effect and uses thereof | 杭州中美华东制药有限公司 | 2025-04-18 | — | — | CN | disclosed |
| CN-117843460-A | Preparation method for producing 10, 10-dimethyl anthrone | 中国科学院大连化学物理研究所 | 2024-04-09 | — | — | CN | disclosed |
| CN-117843460-A | Preparation method for producing 10, 10-dimethyl anthrone | 中国科学院大连化学物理研究所 | 2024-04-09 | — | — | CN | disclosed |
| CN-117820576-A | Polycrystal phase block polymer based on active anion polymerization method and synthetic method thereof | 大连理工大学 | 2024-04-05 | — | — | CN | disclosed |
| CN-111479799-B | Organic compound and organic electroluminescent element comprising same | 斗山索如始株式会社 | 2024-03-01 | — | — | CN | disclosed |
| WO-2023185821-A1 | 1,4-DIHETEROCYCLIC SUBSTITUTED AROMATIC RING OR AROMATIC HETEROCYCLIC COMPOUND AND USE THEREOF | 广州必贝特医药股份有限公司 | 2023-10-05 | — | — | WO | disclosed |
| US-11655504-B2 | High intensity labeled reactant compositions and methods for sequencing | Quantum-Si Incorporated (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220275350-A1 | CIRCULARLY PERMUTATED HALOALKANE TRANSFERASE FUSION MOLECULES | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V. (DE) | 2022-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655504-B2 | High intensity labeled reactant compositions and methods for sequencing | NSUN2, FBL, DNMT3A | HTR2A 1648/4885HTR2C 1931/4885DRD2 3006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.